Competition Law and Bioinformatics Ecosystem Market Power

1. Introduction

The bioinformatics ecosystem combines biological data, genomic sequencing, computational biology, artificial intelligence, cloud infrastructure, databases, analytical software, laboratory platforms and pharmaceutical/diagnostic applications. Competition concerns arise when control over one layer of this ecosystem gives a firm the ability to influence competition in adjacent layers.

Unlike a conventional pharmaceutical market, bioinformatics markets frequently have multi-sided and data-intensive characteristics. A company may simultaneously control:

• genomic or biological datasets;
• sequencing or diagnostic technology;
• bioinformatics software;
• cloud-computing infrastructure;
• analytical algorithms;
• databases and reference libraries;
• APIs and interoperability standards;
• research platforms;
• laboratory networks; and
• downstream diagnostic or therapeutic applications.

The most significant competition-law question is therefore not simply whether a firm has a large market share, but whether its control over data, infrastructure, interoperability, algorithms or technological standards enables it to exclude competitors or raise their costs.

A particularly important modern example is Illumina/GRAIL, where competition authorities examined the relationship between a dominant next-generation sequencing supplier and a downstream cancer-detection business. The FTC ultimately ordered divestiture, finding that the transaction could harm competition and innovation in multi-cancer early-detection testing.

2. Meaning of the Bioinformatics Ecosystem

The ecosystem can be understood as a chain:

Biological data → Sequencing → Data storage → Bioinformatics analysis → AI/algorithms → Interpretation → Diagnostics/drug discovery → Clinical application

Market power can potentially arise at any of these levels.

A. Data layer

Examples include:

• genomic databases;
• population-genomics datasets;
• clinical-genomic datasets;
• proteomic databases;
• phenotypic datasets;
• longitudinal patient datasets.

Data can become competitively significant where competitors cannot readily reproduce the same scale, quality, diversity or historical depth.

B. Technology layer

This includes:

• DNA/RNA sequencing platforms;
• computational infrastructure;
• laboratory information systems;
• genomic-analysis tools;
• cloud platforms.

C. Software and algorithm layer

Bioinformatics companies may supply:

• sequence-alignment software;
• variant-calling algorithms;
• genomic interpretation tools;
• AI-based diagnostic systems;
• drug-discovery platforms.

D. Downstream application layer

The outputs may be used in:

• cancer diagnostics;
• rare-disease diagnosis;
• precision medicine;
• drug discovery;
• clinical trials;
• agricultural genomics;
• personalized medicine.

3. Applicable Competition-Law Framework

A. Abuse of Dominance

A dominant bioinformatics undertaking may face scrutiny where it:

• refuses access to essential datasets;
• discriminates between downstream users;
• imposes unreasonable licensing terms;
• ties sequencing equipment to proprietary software;
• forecloses competing analytical platforms;
• restricts interoperability;
• imposes exclusivity;
• engages in predatory pricing; or
• uses data obtained from customers to compete against them.

Under Section 4 of the Indian Competition Act, 2002, relevant forms of abuse include:

1. unfair or discriminatory conditions;
2. unfair or discriminatory prices;
3. limitation of production or technical development;
4. denial of market access;
5. tying;
6. leveraging dominance from one relevant market into another; and
7. use of dominance in one market to enter or protect another.

4. Relevant-Market Definition in Bioinformatics

Market definition is particularly complicated because bioinformatics products can be substitutes at one level but complements at another.

Possible relevant markets include:

• NGS sequencing platforms;
• genomic-data analysis software;
• genomic interpretation services;
• clinical bioinformatics;
• genomic databases;
• cloud-based genomic computing;
• AI-based diagnostic analysis;
• genomic testing;
• multi-cancer early-detection testing.

A competition authority may need to determine whether the relevant market is:

broad

"bioinformatics services"

or substantially narrower:

"software for interpretation of next-generation sequencing data for clinical oncology."

The narrower the market, the easier it may be to establish substantial market power where the firm controls a critical input.

5. Sources of Market Power in Bioinformatics

5.1 Data advantages

Large datasets can create substantial competitive advantages.

A bioinformatics platform may possess:

• millions of genomic sequences;
• proprietary annotations;
• patient outcome information;
• historical clinical information;
• disease-specific datasets.

A competitor may theoretically build another database, but the cost and time required can create a significant barrier to entry.

However, large data holdings do not automatically establish dominance. Competition analysis should consider:

• replicability;
• data quality;
• switching costs;
• access alternatives;
• data portability;
• interoperability;
• usefulness of the dataset;
• technological change.

6. Network Effects

Bioinformatics platforms can exhibit network effects.

For example:

More researchers → more data → better algorithms → more users → more researchers

This can create a self-reinforcing ecosystem.

A platform may consequently become difficult to challenge even without traditional physical infrastructure.

Competition authorities may therefore examine whether:

• the platform is closed;
• users can export their data;
• APIs are available;
• competing software can interoperate;
• data can be transferred;
• proprietary formats prevent switching.

7. Switching Costs

Bioinformatics customers may invest heavily in:

• software integration;
• laboratory workflows;
• training;
• data migration;
• validation;
• regulatory compliance;
• API integration.

Consequently, switching from one platform to another may be costly.

A dominant firm could potentially exploit this by:

• increasing licence prices;
• restricting data export;
• changing API access;
• making interoperability difficult;
• imposing contractual restrictions.

8. Vertical Integration

Vertical integration is particularly important.

A company might control:

sequencing equipment → sequencing software → genomic database → interpretation software → diagnostic product.

This creates the possibility of input foreclosure.

The vertically integrated company could potentially make competing downstream companies dependent upon its technology.

This was central to the concerns surrounding Illumina/GRAIL. Illumina supplied next-generation sequencing technology, while GRAIL developed multi-cancer early-detection testing relying on sequencing technology. The FTC argued that the acquisition could give Illumina the ability and incentive to disadvantage competing MCED developers.

9. Six Important Case Laws

Case 1: FTC v. Illumina, Inc. / Illumina–GRAIL

Facts

Illumina was a major supplier of next-generation sequencing platforms. GRAIL developed a multi-cancer early-detection test using DNA sequencing.

The FTC challenged Illumina's acquisition of GRAIL.

Competition issue

The central theory was vertical foreclosure.

Illumina supplied an important input required by GRAIL's competitors. By acquiring GRAIL, Illumina would also become a downstream competitor.

The concern was that Illumina might have both:

• the ability to disadvantage competing developers; and
• the incentive to do so.

The FTC ultimately ordered divestiture of GRAIL in 2023. The Fifth Circuit subsequently found substantial evidence supporting the FTC's ruling on the anticompetitive nature of the transaction, while remanding on the treatment of one aspect of Illumina's rebuttal evidence. Illumina then announced that it would divest GRAIL.

Bioinformatics significance

This is arguably the most directly relevant modern precedent for the bioinformatics ecosystem.

It demonstrates that competition law can examine:

control over an upstream technological platform + downstream participation in an innovative market.

It is especially relevant to:

• sequencing platforms;
• genomic diagnostics;
• AI diagnostics;
• clinical bioinformatics;
• proprietary analytical platforms.

Case 2: Illumina Inc. v. European Commission — C-611/22 P and C-625/22 P

The European proceedings concerned the same Illumina/GRAIL transaction but raised an additional jurisdictional issue.

The European Commission investigated the transaction following an Article 22 referral mechanism.

In September 2024, the Court of Justice considered whether the Commission could examine a concentration following a referral request from a national competition authority that itself did not have jurisdiction to review the transaction under its national merger-control thresholds.

Competition significance

The case is important for low-turnover/high-innovation transactions.

Bioinformatics start-ups may have:

• low current revenue;
• valuable datasets;
• proprietary algorithms;
• high future competitive significance.

Traditional turnover thresholds may therefore fail to capture strategically important acquisitions.

Bioinformatics lesson

Competition authorities may increasingly examine:

nascent competitors + innovation assets + strategic data + technological bottlenecks.

Case 3: IMS Health GmbH & Co. OHG v NDC Health — C-418/01

This European competition-law case concerned access to a commercially important information structure.

IMS Health possessed a system for pharmaceutical sales information based on regional structures used by pharmaceutical companies.

The dispute concerned access to the system by competitors.

Competition principle

The case became a leading authority concerning the circumstances in which refusal to license intellectual-property-related assets may constitute an abuse of dominance.

The essential-facilities-type reasoning requires particularly demanding conditions before compulsory access is justified.

Bioinformatics relevance

The analogy is strong where a dominant bioinformatics undertaking controls:

• a unique genomic database;
• proprietary data architecture;
• indispensable analytical infrastructure;
• a standardised data format.

The question would be whether competitors can realistically compete without access.

Case 4: Bronner v Mediaprint — C-7/97

In Oscar Bronner GmbH & Co. KG v Mediaprint, the Court of Justice considered refusal of access to a distribution system controlled by a dominant undertaking.

The Court adopted a restrictive approach to compulsory access.

The fact that an infrastructure is advantageous does not automatically make it an essential facility.

Bioinformatics relevance

Suppose a genomic-data company controls a highly efficient database.

A competitor might argue:

"We cannot compete without access."

Competition law would nevertheless need to determine whether:

1. the input is indispensable;
2. duplication is practically or economically impossible;
3. refusal eliminates effective competition; and
4. there is no objective justification.

Application

This principle can be applied to:

• genomic databases;
• clinical datasets;
• sequencing infrastructure;
• specialist annotation databases;
• proprietary interoperability systems.

Case 5: Microsoft Corp. v Commission — T-201/04

The Microsoft case is important because it demonstrates how interoperability restrictions can produce competition concerns.

The European Commission examined Microsoft's refusal to provide interoperability information to competing work-group server operating systems.

The case concerned the ability of competing products to operate effectively within Microsoft's technological ecosystem.

Bioinformatics relevance

The same logic may arise where a bioinformatics platform:

• refuses API access;
• restricts interoperability;
• uses proprietary data formats;
• prevents third-party software integration;
• limits access to sequencing outputs.

For example:

Sequencer → proprietary data format → proprietary analytics → proprietary clinical interpretation

could create ecosystem dependence.

Competition-law lesson

Interoperability may become a competitive parameter rather than merely a technical issue.

Case 6: Qualcomm — FTC v Qualcomm Inc.

The Qualcomm litigation concerned licensing practices involving cellular technology rather than bioinformatics.

However, it provides useful principles concerning technology bottlenecks, licensing and market power.

The case involved Qualcomm's licensing model and alleged exclusionary practices concerning cellular modem technology.

Bioinformatics analogy

Consider a bioinformatics company controlling an important technological layer:

sequencing technology → essential patents → analytical software → downstream diagnostic applications.

If licensing practices are structured so that competing technologies cannot realistically enter or expand, competition authorities may investigate whether the conduct forecloses competition.

Important distinction

The Qualcomm case should not be treated as a bioinformatics precedent. It is an analogical competition-law precedent concerning technology licensing and exclusion.

10. Additional Relevant Competition Principles

10.1 Aspen Skiing

Aspen Skiing Co. v Aspen Highlands Skiing Corp. is relevant to refusal-to-deal analysis.

Its significance is the possibility that a dominant firm can face antitrust scrutiny when it terminates a previously profitable cooperative relationship under circumstances suggesting exclusionary conduct.

Bioinformatics application

A bioinformatics platform that previously provided:

• API access;
• database access;
• sequencing services;
• interoperability;

might attract scrutiny if it suddenly withdraws access in a way that disadvantages a rival.

However, termination of a commercial relationship is not automatically unlawful.

11. Tying and Bundling

A dominant bioinformatics company could potentially bundle:

sequencing machine + software + database + cloud storage + analytics.

For example:

"Purchase our sequencing platform and you must use our proprietary analytical software."

Potential concerns include:

• foreclosure of competing software;
• increased switching costs;
• exclusion of independent analytics providers;
• leveraging dominance from sequencing into software.

The legal analysis would depend upon market definition, dominance, contractual structure, foreclosure effects and possible efficiencies.

12. Exclusive Dealing

A dominant platform could attempt to require laboratories or hospitals to use:

exclusively its sequencing software or genomic-analysis platform.

Possible competitive effects include:

• preventing rivals from achieving scale;
• denying rivals access to clinical customers;
• increasing entry barriers;
• reinforcing network effects.

However, exclusivity may sometimes generate legitimate efficiencies, such as:

• quality assurance;
• regulatory compliance;
• technical compatibility;
• cybersecurity.

The competition assessment must therefore distinguish legitimate integration from exclusionary foreclosure.

13. Predatory Pricing

Bioinformatics platforms may have:

• high fixed costs;
• low marginal costs;
• significant network effects.

A large incumbent could potentially offer software or analytical services below cost to eliminate competitors and subsequently increase prices.

Competition authorities would normally examine:

• appropriate cost benchmark;
• duration of below-cost pricing;
• recoupment;
• market structure;
• barriers to entry;
• competitive effects.

14. Algorithmic Competition Issues

AI-based bioinformatics introduces another layer.

A dominant platform may use algorithms to determine:

• which genomic analyses are recommended;
• which diagnostic results are prioritised;
• which research tools are displayed;
• which datasets are accessible;
• which third-party applications are promoted.

Competition concerns could arise if the platform systematically favours its own downstream products.

This creates a possible:

self-preferencing + data advantage + vertical integration

problem.

15. Data Access as a Competition Issue

Data access can be divided into four categories:

A particularly important issue is competitor access to aggregated data.

A dominant platform may argue that its database represents a proprietary investment. Competitors may argue that denial of access prevents effective competition.

Competition law therefore has to balance:

innovation incentives vs. competitive access.

16. Intellectual Property and Bioinformatics

Bioinformatics companies may possess:

• patents;
• copyrights;
• database rights;
• trade secrets;
• software rights;
• algorithmic know-how.

IP protection does not itself establish competition-law immunity.

At the same time, competition law generally does not require compulsory licensing merely because a competitor wants access.

The crucial question is whether the exercise of the IP right forms part of conduct that produces legally relevant exclusionary effects.

The IMS Health line of jurisprudence is particularly important in this context.

17. Merger Control in Bioinformatics

Potentially problematic transactions include:

Horizontal mergers

Bioinformatics company A + Bioinformatics company B

Possible concerns:

• loss of innovation;
• data concentration;
• reduced software competition.

Vertical mergers

Sequencing platform + diagnostic company

Potential concerns:

• input foreclosure;
• customer foreclosure;
• discriminatory access.

Conglomerate mergers

Cloud provider + genomic database + AI diagnostic company

Potential concerns:

• tying;
• bundling;
• ecosystem foreclosure;
• leveraging.

Killer acquisitions

A large incumbent may acquire a small bioinformatics start-up before it becomes a meaningful competitor.

Important indicators include:

• patents;
• datasets;
• algorithms;
• researchers;
• pipeline products;
• customer adoption;
• potential future competition.

18. Innovation Competition

Bioinformatics competition is frequently innovation-based rather than price-based.

A transaction or conduct may be harmful even where:

• prices remain constant;
• current output remains constant;
• consumers currently have several products.

The concern may instead be:

Will fewer independent firms develop the next generation of genomic technologies?

The Illumina/GRAIL proceedings illustrate this forward-looking concern. The FTC specifically identified potential harm to competition and innovation in multi-cancer early-detection testing.

19. Essential-Facility-Type Problems

A bioinformatics platform may potentially become an essential facility where it controls infrastructure that competitors cannot reasonably replicate.

Possible examples:

• unique clinical-genomic database;
• national-scale genomic repository;
• specialised sequencing infrastructure;
• indispensable interoperability standard.

But "important" is not synonymous with "essential."

Authorities should investigate:

1. indispensability;
2. replicability;
3. alternative suppliers;
4. technical feasibility;
5. economic feasibility;
6. impact of refusal;
7. objective justification.

20. Competition Concerns in the Indian Context

For India, the Competition Act, 2002 provides the principal framework.

Particularly relevant provisions include:

Section 3

Potentially relevant to:

• data-sharing agreements;
• research collaborations;
• joint purchasing;
• information exchange;
• algorithmic coordination;
• licensing arrangements.

Section 4

Relevant to:

• refusal to deal;
• discriminatory access;
• tying;
• leveraging;
• exclusionary pricing;
• denial of market access.

Sections 5 and 6

Relevant to mergers and acquisitions involving:

• sequencing companies;
• diagnostics companies;
• pharmaceutical companies;
• cloud providers;
• AI companies;
• genomic databases.

21. Possible Competitive Harm Model

A useful analytical model is:

Control of Data

↓

Data Advantage

↓

Algorithmic Advantage

↓

Better Product

↓

More Customers

↓

More Data

↓

Higher Entry Barriers

This can create a data-network-effect feedback loop.

Competition authorities should therefore ask whether the advantage results from legitimate innovation or from exclusionary conduct.

22. Defences and Efficiency Arguments

A bioinformatics company may argue that restrictive practices are justified because they provide:

• cybersecurity;
• patient privacy;
• data integrity;
• clinical accuracy;
• regulatory compliance;
• quality control;
• interoperability protection;
• R&D incentives.

These arguments can be legitimate.

For example, restricting unrestricted access to genomic data may be necessary because of:

• patient confidentiality;
• consent restrictions;
• genetic privacy;
• cybersecurity;
• research ethics.

Consequently, competition law must avoid treating every access restriction as anticompetitive.

23. Remedies

Possible remedies include:

Structural remedies

• divestiture;
• separation of business units;
• sale of databases or technology assets.

Behavioural remedies

• API access;
• interoperability obligations;
• non-discrimination requirements;
• licensing commitments;
• data portability;
• restrictions on exclusivity.

Merger remedies

• firewalls;
• access commitments;
• licensing;
• supply commitments;
• independent governance.

For a highly integrated bioinformatics ecosystem, behavioural remedies may be technically difficult to monitor, while structural separation may be more effective in certain circumstances.

24. Summary of the Six Core Cases

25. Conclusion

Competition law in the bioinformatics ecosystem is moving beyond traditional questions of price and market share toward questions of data, interoperability, innovation, algorithms and ecosystem control.

The central competition risks are:

1. data concentration;
2. sequencing-platform dominance;
3. vertical foreclosure;
4. refusal of access to important datasets;
5. interoperability restrictions;
6. tying and bundling;
7. exclusive dealing;
8. algorithmic self-preferencing;
9. technology-licensing restrictions;
10. acquisition of emerging bioinformatics competitors; and
11. reduction of innovation competition.

The Illumina/GRAIL litigation is particularly significant because it demonstrates how competition authorities can examine the interaction between an upstream genomic technology platform and a downstream innovative diagnostic market. The European proceedings additionally demonstrate the importance of merger-control jurisdiction for transactions involving innovative businesses whose present turnover may not reflect their competitive significance.